PROView

by GE Medical Systems SCS  · Based in France → — AI-powered diagnostic software for comprehensive prostate MRI analysis and reporting.
Oncology Radiology Urology
Website
Claim this tool
Is this the maker? Claim the company →

Contact vendor for details
Regulatory Status Disclosed

Overview

PROView, developed by GE Medical Systems SCS (now part of GE HealthCare), is an advanced medical diagnostic software that leverages deep learning for the review, assessment, and reporting of multi-parametric prostate magnetic resonance (MR) images. It is explicitly designed to aid clinicians, radiologists, and physicians in following PI-RADS guidelines for prostate cancer assessment. This tool is not a physician directory.

The software provides a guided workflow for standardized assessment, including automated prostate segmentation, measurement of prostate and lesion volumes, and scoring of T2-weighted, diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE) acquisitions. It integrates patient clinical history, such as PSA levels, and automatically generates comprehensive reports with all measurements and selected images, which can be exported for seamless integration into external reporting solutions or PACS. PROView aims to deliver consistent quantification results and enhance the efficiency and accuracy of prostate MR exam interpretation and communication to referring physicians.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Deep learning-based automated prostate segmentation for consistent quantification results
  • Guided workflow for simple and standardized assessment of multi-parametric prostate MR series
  • Alignment with PI-RADSu00ae v2.1 guidelines for review, assessment, and reporting
  • Tools for prostate gland volume calculation and lesion analysis
  • Scoring of T2-weighted, diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE) acquisitions
  • Automated report generation with all measurements and selected images
  • Export reports in HTML, PDF, and DICOM for integration into external reporting solutions or PACS
  • Intelligent display of multi-parametric prostate MR series along with patient clinical history (e.g., PSA levels)
  • Facilitates communication of findings to referring physicians
  • Integration with ultrasound-based fusion systems for biopsy guidance

Use Cases

  • Review and assessment of multi-parametric prostate MR images
  • Aid in prostate cancer evaluation and diagnosis
  • Standardized reporting of prostate MRI findings according to PI-RADS guidelines
  • Support for treatment planning based on prostate lesion analysis
  • Enhancing consistency in prostate MRI interpretation across users
  • Exporting data for integration with ultrasound-based fusion systems for targeted biopsies

What Physicians Need to Know

Key Capabilities
PROView leverages deep learning for automated prostate segmentation, providing consistent quantification results. It offers a guided workflow for standardized assessment, including an intelligent display of multi-parametric prostate MR series and patient PSA levels. The system includes tools for lesion localization and reporting on a PI-RADS sector map, enabling lesion mapping to sectors and measurement for peripheral and transitional zones, and scoring of T2-weighted, diffusion-weighted imaging (DWI) with integrated apparent diffusion coefficient (ADC) maps, and dynamic contrast-enhanced (DCE) acquisitions. It also automates contouring and measurement of the prostate gland for volume calculation and extraction, and automated calculation of PSAD. PROView can segment, measure, and export high-quality MRIs to ultrasound-based fusion systems.
Clinical Utility
PROView is a review and reporting tool for prostate MR that applies the PI-RADS® v2.1 guidelines for the evaluation of prostate cancer. It aims to standardize prostate reporting, facilitating interdisciplinary agreement between urologists and radiologists for patient follow-up. The tool helps in determining PSA density and prostate volume, which are crucial for managing PI-RADS® category 3 patients who may be deferred for repeat biopsy. By enabling the segmentation and export of high-quality MRIs to ultrasound-based fusion systems, PROView assists in providing real-time guidance for biopsies, helping physicians target suspicious regions and potentially reducing false negatives due to incomplete sampling. This can lead to more accurate Gleason scores by targeting the most aggressive parts of heterogeneous tumors.
Integration Options
PROView integrates with standard dictation reporting systems. Reports generated by PROView, including measurements and images, can be exported into HTML for seamless integration into external reporting solutions or saved through PDF and DICOM to PACS. The software allows high-quality MRIs to be segmented, measured, and exported to ultrasound-based fusion systems.
Compliance Status
GE HealthCare has a comprehensive compliance program that aligns with U.S. federal and state laws, including elements for California law, and industry guidelines such as the PhRMA Code and AdvaMed Code. The company states it is in compliance with its compliance policies and California requirements in all material respects. GE HealthCare's compliance organization, led by a Chief Compliance Officer, is responsible for developing, operating, and monitoring the program, and has the authority to recommend and implement changes. The program includes policies and procedures like a Code of Ethics & Integrity and a Global Interactions Policy, addressing ethical marketing promotion and applicable laws. Employees can contact the Compliance Department directly or use a compliance hotline for inquiries or to report concerns anonymously.
Pricing Model
The pricing for GE Healthcare's software, including PROView, is customizable and flexible, varying based on the organization's size and specific requirements. GE Healthcare offers subscription models for its imaging technologies, such as Smart Subscription, which includes updates and upgrades for an annual fee per device.
User Experience
PROView features a guided workflow for simple and standardized assessment. GE Healthcare generally focuses on simplifying the user experience (UX) in its products, aiming for intuitive workflows and ease of use. The company's SIGNA One imaging platform, for example, features a new user interface designed for intuitive workflow, efficiency, simplicity, and intelligent automation. This focus on user-friendly interfaces is intended to reduce the learning curve for technologists and improve workflow productivity.
Support Quality
GE HealthCare provides world-class service solutions, employing certified field engineers who undergo the latest technical training. They offer equipment maintenance to optimize performance and digital solutions with remote support to ensure imaging technology readiness. Healthcare IT support is available for Centricity solutions. GE also provides support documentation and site planning assistance for the design and implementation of its equipment. The company's implementation process involves a project team of both GE and hospital personnel, with a GE Project Manager or Account Coordination Specialist serving as the primary contact. GE's implementation team assists with GoLive operations and issue resolution.
Implementation Complexity
The implementation of GE Healthcare systems, including software, involves a team effort between the customer and GE. The complexity, schedule, and cost of the project are influenced by the specific site selected and the type of system. GE provides implementation documentation and works with the customer on planning, installation, configuration, testing, and activation. The customer is responsible for providing and supporting peripheral interfaces, communication configurations, and technical support to GE staff. They also need to ensure timely availability of customer-supplied equipment and resources for system testing and training.
Evidence Base
PROView leverages deep learning for automated prostate segmentation. GE HealthCare is a leader in AI-enabled medical devices and has received numerous FDA authorizations for its AI solutions. The company actively conducts research and integrates AI into its imaging and monitoring devices to enhance efficiency and care quality. GE HealthCare's AI innovations aim to redefine possibilities in healthcare diagnosis, treatment, and patient care. The company's AI-powered tools are designed to reduce clinician workload and provide personalized patient experiences.
Physician Tip

PROView can significantly enhance prostate MR interpretation by providing automated segmentation and standardized reporting aligned with PI-RADS® v2.1 guidelines. This can lead to more consistent quantification and improved interdisciplinary communication. Leveraging its ability to export segmented MRIs to ultrasound-based fusion systems can improve biopsy targeting and potentially reduce false negatives. Pay close attention to the automated calculation of PSA density and prostate volume, as these are critical for managing PI-RADS® category 3 patients.

PROView is designed to integrate with existing clinical workflows. It can export reports in HTML for external reporting solutions and save them as PDF and DICOM files to PACS. The software's capability to export segmented and measured MRIs to ultrasound-based fusion systems is a key integration point for guided biopsies.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Contact vendor for details
DeploymentOn-premise (via GE provided server within facility's firewall, often through a Smart Subscription model)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status Yes AI-estimated
Integrations
EHR Not specified
Specialties Oncology, Radiology, Urology

What the Web Says

GE HealthCare's PROView is a review and reporting tool for prostate MR that utilizes deep learning for automated prostate segmentation and applies PI-RADS® v2.1 guidelines for prostate cancer evaluation. It aims to provide consistent quantification results and a standardized assessment workflow, including an intelligent display of multi-parametric prostate MR series and patient PSA levels. The software also offers tools for lesion localization and reporting on a PI-RADS sector map. Overall, GE HealthCare products, including their EHR software, receive mixed to positive reviews, with users often praising functionality and customer support but noting areas for improvement in user interface modernity and cost. While specific reviews for "PROView" itself are limited, the broader sentiment towards GE HealthCare's software solutions suggests a focus on robust features and reliability, though some find the interface dated and pricing a concern.

Overall: Mixed

Strengths

  • Automated prostate segmentation using deep learning for consistent quantification.
  • Guided workflow for simple and standardized assessment.
  • Intelligent display of multi-parametric prostate MR series and patient PSA levels.
  • Dedicated tools for lesion localization and PI-RADS sector map reporting.
  • Integration with third-party software.
  • Strong customer support for GE Healthcare products.

Limitations

  • Interface could be more contemporary.
  • Can be expensive, with additional costs for customization or extra features.
  • Occasional connectivity issues.
  • Reports can take a while to generate.
  • Lack of real-time spell check.
  • Inability to open multiple tabs simultaneously.

Based on reviews from: comparably.com, softwarefinder.com, featuredcustomers.com, capterra.com, g2.com, rfp.wiki, indeed.com, reddit.com, gehealthcare.com

Last updated: 2026-10-30

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate PROView

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

GE HealthCare
GE HealthCare introduces PROView software for enhanced prostate MRI analysis
GE HealthCare has recently introduced PROView, a prostate reporting package that includes software allowing high-quality MRIs to be segmented, measured, and exported to ultrasound-based fusion systems for improved biopsy guidance. This software leverages deep learning for automated prostate segmentation, aiming to deliver consistent quantification results and includes dedicated tools for lesion localization and reporting on a PI-RADS sector map.
2026-10
GE HealthCare
GE HealthCare reports third quarter 2026 financial results
GE HealthCare announced strong financial results for the third quarter ended September 30, 2026, with revenues of $5.5 billion, up 7.2%, and organic revenue growth of 6.2%. The company also reported a net income attributable to GE HealthCare of $615 million and raised its full-year 2026 guidance.
2026-10
GE HealthCare
GE HealthCare to acquire SOFIE Biosciences
GE HealthCare announced its plan to acquire SOFIE Biosciences for $945 million in cash, a move expected to establish a 'final mile' footprint for PET radiopharmaceutical supply in the U.S. The transaction is anticipated to close in the first half of 2027, pending regulatory approvals.
2026-10
GE HealthCare
GE HealthCare and Circle Cardiovascular Imaging introduce MyoFlow
GE HealthCare and Circle Cardiovascular Imaging have partnered to introduce MyoFlow, a solution designed to simplify quantitative cardiac stress perfusion MRI. This collaboration aims to advance cardiac imaging capabilities.
2026-10
GE HealthCare
GE HealthCare announces five new global clinical collaborations to advance theranostics imaging
GE HealthCare has announced five new global clinical collaborations focused on advancing the next generation of theranostics imaging. These collaborations underscore GE HealthCare's commitment to innovation in precision medicine.
2026-10
GE HealthCare
GE HealthCare expands general imaging ultrasound portfolio with LOGIQ Focus
GE HealthCare has expanded its general imaging ultrasound portfolio with the introduction of LOGIQ Focus, aiming to elevate everyday ultrasound performance. This expansion reflects the company's investment in the growing ultrasound market.
2026-10
GE HealthCare
GE HealthCare's MINItrace™ Magni achieves CE Mark
GE HealthCare's MINItrace™ Magni has achieved CE Mark approval, expanding the PETtrace™ Solid Target Platform to include Copper-64 beyond Gallium-68. This regulatory milestone enhances the company's offerings in radiopharmaceuticals.
2026-10
GE HealthCare
GE HealthCare announces U.S. FDA 510(k) clearance for View
GE HealthCare announced that View, a powerful viewer within the Genesis™ Radiology Workspace, received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This next-generation diagnostic viewer is designed to transform radiology workflows and provide anywhere-access for radiologists.
2026-03

Videos

Product demos, reviews, and walkthroughs for PROView.

View all on YouTube

Frequently Asked Questions

GE HealthCare PROView is an AI-powered solution that leverages deep learning for automated prostate segmentation in MRI scans. It provides consistent quantification results and a guided workflow for standardized assessment, including an intelligent display of multi-parametric prostate MR series and patient PSA levels. This technology aids in prostate cancer diagnosis, treatment planning, and monitoring by enabling automated contouring and measurement of the prostate gland, calculation of PSA density, and tools for lesion localization and PI-RADS reporting.
PROView is designed to integrate into existing clinical workflows, providing automated segmentation and quantitative analysis to enhance efficiency and decision-making in prostate MRI. While specific compliance standards for PROView are not detailed, GE HealthCare emphasizes that its AI solutions are developed with patient safety as a top priority and aims to comply with regulatory requirements. GE HealthCare also offers other AI-enabled devices that have received FDA authorizations, indicating a commitment to regulatory compliance for its AI products.
While the prompt specifically asks about PROView, GE HealthCare offers a broader portfolio of AI-powered oncology solutions, including CareIntellect for Oncology, which integrates multi-modal patient data and uses generative AI to summarize clinical notes and reports for various cancers, including prostate and breast cancer. Other companies also offer AI tools for oncology, focusing on areas like tumor detection, treatment planning, and patient management, though specific direct alternatives to PROView's prostate segmentation capabilities are not detailed in the provided information.
While AI tools like PROView offer significant benefits, general limitations of AI in oncology include potential inconsistencies in performance after deployment, biases in algorithm development, and data-related challenges such as inconsistent quality and limited representativeness of datasets. Over-reliance on AI could also potentially erode clinical expertise. For PROView specifically, while it automates segmentation, clinicians still need to interpret the results in the context of the patient's overall clinical picture.
Specific pricing for GE HealthCare PROView is not publicly available in the provided information. However, GE HealthCare does offer financing options for its healthcare technology. They also provide subscription-based services for CT applications, suggesting a potential for similar models for other AI solutions.

Related Tools

SOPHiA DDM
SOPHiA GENETICS
Oncology AI
SOPHiA DDM™ is an AI-driven and cloud-powered platform that helps clinicians generate real-time, actionable insights for patients with cancer and rare disorders by analyzing complex genomic, radiomic, and multimodal data.
Paid
CerviCARE AI
NTL Healthcare
OB/GYN AI
CerviCARE AI is an AI-powered cervical cancer screening system that analyzes smartphone images of the cervix to predict findings, aiming for early detection.
Lumonus AI
Lumonus
Clinical Decision Support & Reference
Lumonus AI is an AI-powered software that assists healthcare providers with prescriptions, dosing, and treatment for cancer patients, with a module (Sigma) that suggests treatment protocols based on prior plans for similar patients.
DeepBio DeepDx® Prostate
DeepBio
Oncology AI
DeepDx® Prostate leverages deep learning to standardize prostate cancer diagnostics by detecting abnormalities in digital slides with high precision, providing automated Gleason grading, tumor quantification, and tumor length measurements.
AIRA Matrix AI Solutions
AIRA Matrix
Lab & Diagnostics
AIRA Matrix offers AI solutions to improve efficiency and diagnostic accuracy in pathology lab workflows, primarily for prostate and breast cancer, with services like DPaaS and predictive toxicology.
Surgical Reality Viewer
Surgical Reality
Oncology AI
Surgical Reality offers CE- and FDA-certified AI-powered 3D medical imaging and surgical planning software that transforms CT scans into patient-specific 3D models for thoracic surgery, enhancing precision in complex lung procedures.

See all Oncology AI tools →

More from GE Medical Systems SCS

3DXR
GE HealthCare
Radiology & Imaging AI
3DXR is an AI-powered post-processing software by GE HealthCare that performs 3D reconstruction of X-ray interventional images, enhancing clarity by reducing artifacts for improved diagnosis and surgical planning.
Bone VCAR (BVCAR)
GE HealthCare
Radiology & Imaging AI
Bone VCAR by GE Medical Systems SCS is an FDA-cleared, deep learning-based AI tool for automated CT spine analysis, designed to improve reading efficiency and reporting by providing automated spine labeling and reformat generation.
CardIQ Suite
GE HealthCare
Cardiology AI
CardIQ Suite is an AI-powered cardiac CT post-processing application by GE Medical Systems SCS, offering automated calcium scoring and CCTA review for comprehensive cardiovascular disease diagnosis and treatment planning.
FlightPlan for Embolization
GE Medical Systems SCS
Radiology & Imaging AI
FlightPlan for Embolization is an FDA-cleared AI-powered software by GE Medical Systems SCS that processes 3D X-ray angiography images to assist physicians in visualizing vasculature and planning embolization procedures.
Contact for pricing

View company profile →

Suggest an Edit → | Report an issue | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.